Johnson & Johnson (JNJ) Advances Bladder Cancer Treatment with 89% Response Rate

Pixabay/Public Domain

According to the company, the proceedings met its large information goals. The intermediate-risk illustration of 62 patients had an 89% implicit effect rate, with a median magnitude of 18 months.

Johnson & Johnson (NYSE:JNJ) besides stated connected March 12 that the FDA had approved its TECNIS PureSee IOL, an expanded extent of absorption intraocular lens for cataract surgery. The lens is associated with JNJ’s TECNIS portfolio, which besides includes the TECNIS Odyssey and TECNIS Eyhance IOLs. The institution stated that millions of patients astir the satellite person TECNIS lenses each twelvemonth arsenic portion of their cataract treatment.

Johnson & Johnson (NYSE:JNJ) is simply a diversified healthcare company. It operates done 3 main segments: Innovative Medicine, MedTech, and Consumer Health. Its merchandise scope includes pharmaceuticals and aesculapian devices, arsenic good arsenic wide recognized user brands.

While we admit the imaginable of JNJ arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.